美沙拉嗪缓释颗粒治疗溃疡性结肠炎的疗效及对患者TNF-α、IL-8的影响  

Clinical effects of mesalazine sustained-release granules in treatment of ulcerative colitis and its influences on serum TNF-α and IL-8

作　　者：董力[1] 王建[1] 贾晨虹[1] 

机构地区：[1]河北省廊坊市人民医院药学部,河北廊坊065000

出　　处：《实用临床医药杂志》2014年第24期53-56,共4页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(11321478)

摘　　要：目的观察美沙拉嗪缓释颗粒治疗溃疡性结肠炎(UC)的疗效及对患者血清肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)的影响。方法选取2012年1月—2013年6月UC活动期患者89例,随机分为美沙拉嗪组46例和柳氮磺吡啶(SASP)组43例。美沙拉嗪组给予美沙拉嗪缓释颗粒口服,SASP组给予SASP片口服。观察2组临床疗效及治疗前后Sutherland评分变化、不良反应、治疗前后血清TNF-α、IL-8水平变化,以及随访情况。结果美沙拉嗪组总有效率93.48%,SASP组总有效率79.07%,2组差异显著(P<0.05);2组治疗后Sutherland评分均较治疗前显著降低,美沙拉嗪组显著低于SASP组(P<0.01);2组治疗后血清TNF-α、IL-8水平均较治疗前显著降低,组间差异显著(P<0.01)。随访6个月后,美沙拉嗪组Sutherland评分低于SASP组(P<0.01),2组复发率无显著差异(P>0.05)。结论美沙拉嗪治疗UC的疗效优于SASP,且可有效降低患者血清TNF-α、IL-8水平。ABSTRACT： Objective To investigate mesalazine sustained-release granules in treatment of ulcerative colitis （UC） and its influences on serum tumor necrosis factor-α （ TNF-α）, and interleukin- 8 （IL-8）. Methods A total of 89 patients with active UC were randomly divided into mesalazine group （with oral administration of Mesalazine sustained-release granules, n = 46 ） and sulfasalazine （SASP） group （with oral administration of SASP tablets, n = 43）. Sutherland disease active index, adverse reactions, and serum levels of TNF-α and IL-8 were observed before and after treatment. Re- sults Overall response rate was 93.48 % in mesalazine group and 79.07 % in SASP group, with sig- nificant differences （P 〈 0.05 ）. Sutherland scores were reduced more significantly in mesalazine group than SASP group （P 〈 0.01 ）. Serum levels of TNF-o~, and IL-8 in UC patients were reduced with significant differences between two groups （P 〈0.01 ）. After 6 months follow-up, Sutherland index wa.. lower in mesalazine group than in SASP group （ P 〈 0.01 ）. Conclusion Compared with SASP, mesalazine is more effective in treatment of UC, as well as TNF-α and IL-8 reduction.

关 键 词：溃疡性结肠炎 肿瘤坏死因子-Α 白细胞介素-8 美沙拉嗪 柳氮磺吡啶 细胞因子 

分 类 号：R574.62[医药卫生—消化系统]